Price Alert

Palvella Therapeutics Inc... (PVLA)

NASDAQ: PVLA · Real-Time Price · USD

73.14

-3.17 (-4.15%)

At close: Oct 16, 2025, 3:59 PM

72.00

-1.56%

After-hours: Oct 16, 2025, 05:31 PM EDT

-4.15% (1D)

Bid	60
Market Cap	808.9M
Revenue (ttm)	n/a
Net Income (ttm)	-24.13M
EPS (ttm)	-2.53
PE Ratio (ttm)	-28.91
Forward PE	-20.95
Analyst	Buy
Dividends	n/a

Ask	80
Volume	250,044
Avg. Volume (20D)	180,743
Open	76.69
Previous Close	76.31
Day's Range	71.72 - 77.30
52-Week Range	11.17 - 77.67
Beta	-0.13
Ex-Dividend Date	n/a

About PVLA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PVLA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PVLA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

6 months ago

-15.72%

Palvella Therapeutics shares are trading lower on ... Unlock content with Pro Subscription

8 months ago

+6.26%

Palvella Therapeutics shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and announced a price target of $44.

News

1 week ago · investors.com

Small Stocks Shoot Higher — Here Are 7 Up The Most

Big-cap stocks like Nvidia and Palantir steal attention. But now investors are scoring gains on small caps not in the S&P 500.

3 weeks ago · seekingalpha.com

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Palvella's QTORIN rapamycin is its main value driver. This candidate is in Phase 3 trials for mLM. Management anticipates its top-line data by Q1 2026, with a potential NDA planned by 2H2026. If appro...

1 month ago · https://thefly.com

Palvella Therapeutics price target raised to $66 from $52 at Canaccord

Canaccord raised the firm's price target on Palvella Therapeutics to $66 from $52 and keeps a Buy rating on the shares. The firm said its 2Q25 earnings report was incremental following enrollment comp...

2 months ago · https://thefly.com

Palvella Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Palvella Therapeutics with an Outperform rating and $54 price target. The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to ...